Company Filing History:
1 out of 34 
1 out of 5 
1 out of 1 Years Active: 2014-2025
Title: Innovations and Contributions of Inventor Hong Tian
Introduction
Hong Tian is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of peptides and recombinant proteins. With a total of 2 patents, his work has the potential to impact vaccine development and cancer treatment.
Latest Patents
One of Hong Tian's latest patents is titled "Helper epitope peptide and application thereof." This invention involves a helper epitope peptide obtained by replacing one or two amino acid residues in the helper T cell epitope PADRE with 4-nitrophenylalanine. The helper epitope peptide is effective for enhancing the immunogenicity of an antigen or antigenic epitope, and it can be used for preparing or constructing a vaccine.
Another significant patent is "Modified recombinant human endostatin and uses thereof." This invention provides a modified recombinant human endostatin with a specific structure that enhances stability in vivo, improves blood drug concentration, and prolongs half-life. It markedly increases the activity of inhibiting endothelial cell proliferation, thus reducing drug dosage and decreasing administration frequency. This modified endostatin has applications in preparing anti-tumor pharmaceutical compositions.
Career Highlights
Hong Tian has worked with prominent institutions such as China Pharmaceutical University and Jiangsu Simcere Pharmaceutical R&D Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical research and development.
Collaborations
Hong Tian has collaborated with notable colleagues, including Wenbing Yao and Xiangdong Gao. These partnerships have likely facilitated the advancement of his research and innovations.
Conclusion
In summary, Hong Tian is an accomplished inventor whose work in peptide and recombinant protein development holds promise for future medical applications. His patents reflect a commitment to enhancing immunogenicity and improving cancer treatment options.